The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
 
Makoto Maemondo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Taiho Pharmaceutical (Inst)
 
Tatsuro Fukuhara
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celltrion (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Roche (Inst)
 
Haruhiro Saito
Honoraria - Bristol-Myers Squibb Japan; Nippon Boehringer Ingelheim; Novar Pharma; Ono Pharmaceutical
Patents, Royalties, Other Intellectual Property - AstraZeneca (Inst); Chugai Pharma (Inst)
 
Naoki Furuya
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
 
Kana Watanabe
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Shunichiro Iwasawa
Speakers' Bureau - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Yoshio Tsunezuka
No Relationships to Disclose
 
Ou Yamaguchi
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Kouzou Yoshimori
No Relationships to Disclose
 
Ichiro Nakachi
No Relationships to Disclose
 
Akihiko Gemma
Consulting or Advisory Role - Nihonkayaku
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb
 
Koichi Azuma
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Ono Pharmaceutical
 
Koichi Hagiwara
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyorin; MSD Oncology; Novartis; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma
Research Funding - Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - LSI Medience Corporation
 
Toshihiro Nukiwa
No Relationships to Disclose
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly; Merck Sharp & Dohme; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Nippon Boehringer Ingelheim (Inst)
 
Kunihiko Kobayashi
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical